U.S. Viscosupplementation Market Expands with Technological Innovations in Hyaluronic Acid

 The U.S. viscosupplementation market is on a path of stable expansion, supported by rising cases of osteoarthritis, advancements in treatment options, and growing patient awareness of minimally invasive therapies. According to industry projections, the market is expected to be valued at US$1,127.6 million in 2025 and reach US$1,611.7 million by 2032, growing at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2032.

Market Overview

Viscosupplementation involves the injection of hyaluronic acid (HA) into joints, primarily the knee, to improve lubrication and reduce pain caused by osteoarthritis. The therapy is increasingly preferred as an alternative to oral medications and surgical interventions, owing to its minimally invasive nature and effectiveness in alleviating discomfort. With osteoarthritis becoming more prevalent among the U.S. population, particularly within the aging demographic, demand for viscosupplementation treatments continues to climb.

The U.S. market represents one of the most lucrative regions globally, driven by the presence of leading pharmaceutical and medical device companies, strong healthcare infrastructure, and robust reimbursement frameworks.

Historical Performance

Between 2019 and 2024, the U.S. viscosupplementation market witnessed steady growth, despite challenges posed by the COVID-19 pandemic. While elective procedures were temporarily deferred, the subsequent resumption of treatments led to a rebound in demand. Increased adoption of single-injection therapies and technological advancements in hyaluronic acid formulations helped support market recovery.

Key Growth Drivers

Rising Prevalence of Osteoarthritis

Osteoarthritis affects millions of Americans, with the knee being the most common site of affliction. According to the Centers for Disease Control and Prevention (CDC), nearly 32.5 million adults in the U.S. live with osteoarthritis. The condition is strongly linked to aging, obesity, and sedentary lifestyles—factors that are intensifying in the country. As a result, the patient pool for viscosupplementation therapy continues to expand.

Shift Toward Minimally Invasive Treatments

Many patients prefer to delay or avoid joint replacement surgery due to its cost, recovery time, and potential complications. Viscosupplementation offers a minimally invasive alternative that can provide months of pain relief, making it an attractive option for both patients and physicians.

Product Innovations and FDA Approvals

Continuous research and development have led to improved viscosupplementation products, including high-molecular-weight hyaluronic acid formulations and cross-linked products that enhance efficacy. Regulatory approvals in the U.S. market for novel formulations have boosted adoption.

Increasing Awareness and Reimbursement Support

Rising patient awareness campaigns and physician advocacy for viscosupplementation are supporting growth. Additionally, reimbursement coverage for hyaluronic acid injections under Medicare and private insurance plans has improved accessibility.

Market Challenges

While the outlook for the U.S. viscosupplementation market is positive, certain barriers remain. The high cost of treatments compared to oral pain medications, variability in patient response, and clinical debates around long-term efficacy may restrain adoption. Furthermore, competitive therapies such as platelet-rich plasma (PRP) injections and stem cell treatments are emerging as alternatives, potentially creating headwinds for viscosupplementation.

Market Segmentation

By Product

• Single Injection Viscosupplementation: This segment is gaining popularity due to its convenience, reduced number of hospital visits, and lower risk of infection. Physicians and patients alike increasingly favor single-injection options, making it one of the fastest-growing categories.

• Three Injection Viscosupplementation: Traditionally the most widely used regimen, this segment continues to hold a significant share of the market. However, its growth is slower compared to single-injection treatments.

• Five Injection Viscosupplementation: Once dominant, this segment is gradually losing favor due to the burden of multiple clinical visits and higher cumulative treatment costs.

By Application

• Knee Osteoarthritis: The largest application segment, knee osteoarthritis accounts for the majority of viscosupplementation procedures. Rising obesity rates and sports-related injuries contribute significantly to demand.

• Shoulder Osteoarthritis: While smaller in scale, this segment is gaining traction as awareness of viscosupplementation in treating shoulder pain increases.

• Hip Osteoarthritis: Adoption remains moderate due to complexities in administering intra-articular injections for the hip joint.

• Others: Includes ankle and smaller joints where viscosupplementation is being explored as an off-label or adjunctive therapy.

By Distribution Channel

• Hospital Pharmacies: The leading channel, given that viscosupplementation procedures are typically administered in hospitals and clinics.

• Retail Pharmacies: Expected to grow steadily as outpatient prescriptions for hyaluronic acid products expand.

• Online Pharmacies: Though currently a niche segment, e-commerce distribution is rising as patients seek convenient purchasing channels and healthcare providers increasingly rely on digital supply chains.

Competitive Landscape

The U.S. viscosupplementation market is highly competitive, featuring a mix of multinational pharmaceutical companies and specialized medical device firms. Key players include:

• Sanofi S.A.

• Zimmer Biomet Holdings Inc.

• Bioventus LLC

• Anika Therapeutics Inc.

• Fidia Pharma USA Inc.

• Ferring B.V.

• Seikagaku Corporation

• OrthogenRx Inc. (Channel-Markers Medical)

• Medical Device Business Services, Inc. (J&J subsidiary)

• AVNS

• Searchlight Pharma Inc.

• Aptissen GmbH

• Teva Pharmaceutical Industries Ltd.

• TRB Chemedica International SA

• IBSA Institut Biochimique SA

These companies are investing in strategic initiatives such as product launches, partnerships with healthcare providers, acquisitions, and geographic expansions to consolidate market share.

Strategic Growth Initiatives

Several market leaders are focusing on expanding single-injection portfolios and securing regulatory approvals for new formulations. Collaborations with orthopedic specialists and sports medicine clinics are also being emphasized to enhance product adoption. Additionally, digital marketing campaigns and direct-to-consumer awareness initiatives are strengthening brand visibility.

Pricing and Reimbursement Analysis

Pricing of viscosupplementation therapies varies depending on the formulation, number of injections, and brand. Single-injection therapies, while more expensive per dose, are often considered cost-effective due to reduced clinical visits. Favorable reimbursement policies from Medicare and private insurers are critical in driving adoption, though coverage terms vary across states and healthcare providers.

Future Opportunities

Growing Role of E-commerce and Telemedicine

The integration of telemedicine into osteoarthritis management is expected to enhance access to viscosupplementation. Patients may increasingly consult online and order products through digital platforms, creating opportunities for pharmaceutical companies to expand online distribution.

Expansion into Non-Knee Applications

Research into the use of viscosupplementation for joints beyond the knee, such as the hip, ankle, and shoulder, could open new avenues of growth. Positive clinical evidence supporting these applications would broaden the market base.

Emerging Biologic and Combination Therapies

Companies are exploring hybrid therapies that combine hyaluronic acid with biologics such as platelet-rich plasma or corticosteroids. These combination approaches could deliver enhanced efficacy, helping viscosupplementation maintain competitiveness against regenerative therapies.

Market Forecast and Trends

From 2025 to 2032, the U.S. viscosupplementation market is projected to maintain steady growth, reflecting a balance between increasing demand and competitive pressures. Single-injection therapies are expected to dominate, driven by patient preference for convenience and cost-efficiency. Knee osteoarthritis will remain the core application segment, though incremental growth is anticipated in shoulder and hip treatments.

Technological advancements, supportive reimbursement, and patient-centric innovations will drive adoption. At the same time, manufacturers will need to address clinical skepticism and competition from alternative pain management solutions to safeguard growth momentum.

Conclusion

The U.S. viscosupplementation market is on track for healthy expansion, underpinned by demographic shifts, rising osteoarthritis prevalence, and advances in treatment formulations. With projected revenues climbing from US$1,127.6 million in 2025 to US$1,611.7 million by 2032, the industry is set to witness a transformative decade. Companies that embrace innovation, strengthen partnerships with healthcare providers, and capitalize on emerging opportunities will be best positioned to lead in this evolving landscape.